Qu Biologics Inc.
Clinical-stage biotechnology company developing a platform of organ-targeted immunomodulators designed to restore innate immune function in specific tissues. The company conducts preclinical research, translational studies, and randomized Phase 2 clinical trials across oncology, inflammatory bowel disease, respiratory disease, metabolic disease, and immunosenescence; it also pursues manufacturing for clinical supply, regulatory clearances, and partnerships for biomarker and genomic profiling.
Industries
Nr. of Employees
small (1-50)
Qu Biologics Inc.
Patents
Products
Clinical-stage organ-targeted immunomodulator therapeutics (SSI platform)
A platform of organ-targeted immunomodulator drug candidates designed to restore innate immune function locally in specific tissues to treat cancer, inflammatory diseases, and infections.
QBECO
Site-Specific Immunomodulator (SSI) therapeutic candidate positioned for colon cancer, pancreatic cancer, and chronic inflammatory diseases.
QBECO SSI
Derived from inactivated E. coli, targeting the gastrointestinal tract and related organs where E. coli is endogenous and a common cause of infection.
QBSAU
Site-Specific Immunomodulator (SSI) therapeutic candidate in clinical development for melanoma and ovarian cancer.
QBSAU SSI
Derived from inactivated S. aureus, targeting the skin, soft tissue, and bone where S. aureus is a common cause of infection.
QBKPN
Site-Specific Immunomodulator (SSI) therapeutic candidate in clinical development for lung cancer.
Clinical-stage organ-targeted immunomodulator therapeutics (SSI platform)
A platform of organ-targeted immunomodulator drug candidates designed to restore innate immune function locally in specific tissues to treat cancer, inflammatory diseases, and infections.
QBECO
Site-Specific Immunomodulator (SSI) therapeutic candidate positioned for colon cancer, pancreatic cancer, and chronic inflammatory diseases.
QBECO SSI
Derived from inactivated E. coli, targeting the gastrointestinal tract and related organs where E. coli is endogenous and a common cause of infection.
QBSAU
Site-Specific Immunomodulator (SSI) therapeutic candidate in clinical development for melanoma and ovarian cancer.
QBSAU SSI
Derived from inactivated S. aureus, targeting the skin, soft tissue, and bone where S. aureus is a common cause of infection.
QBKPN
Site-Specific Immunomodulator (SSI) therapeutic candidate in clinical development for lung cancer.
Services
Design and conduct of Phase 2 randomized, placebo-controlled clinical studies to evaluate safety, efficacy, and biomarker correlates of organ-targeted immunomodulator therapeutics.
Partnerships with academic research centers for in vivo efficacy studies, mechanistic tissue analyses, and assay development to support clinical translation.
Design and conduct of Phase 2 randomized, placebo-controlled clinical studies to evaluate safety, efficacy, and biomarker correlates of organ-targeted immunomodulator therapeutics.
Partnerships with academic research centers for in vivo efficacy studies, mechanistic tissue analyses, and assay development to support clinical translation.
Expertise Areas
- Clinical trial management
- Organ-targeted innate immunotherapy development
- Translational research and biomarker development
- Preclinical animal efficacy testing
Key Technologies
- Site-specific immunomodulation
- Innate immune training approaches
- Inactivated bacteria–derived immunomodulators
- Preclinical animal disease models
News & Updates
Partnership with an academic pathology group to analyze tissue biopsies from Crohn’s disease patients who experienced histologic healing after treatment, aimed at identifying tissue-level gene expression changes and patient selection biomarkers.
Awarded advisory services and funding from NRC IRAP to support preclinical confirmation, manufacturing in Canada, and regulatory work for a lung-directed immunomodulator intended for prevention and treatment of respiratory viral infections.
Oral presentation of Phase 2 clinical trial data for a GI-targeted immunomodulator showing clinical, endoscopic, and histologic responses in patients with moderate-to-severe Crohn’s disease.
Regulatory clearance to proceed with a randomized placebo-controlled trial evaluating lung-directed immunomodulator in elderly participants to assess effects on innate immunity and respiratory infection outcomes.
Awarded grant funding by the Accelerating Clinical Trials (ACT) consortium to support a Phase 2 perioperative trial assessing reduction of postoperative immune suppression in late-stage colon cancer.
Three-year ARD grant to support preclinical and translational research to expand indications for organ-targeted immunomodulators.
Partnership with an academic pathology group to analyze tissue biopsies from Crohn’s disease patients who experienced histologic healing after treatment, aimed at identifying tissue-level gene expression changes and patient selection biomarkers.
Awarded advisory services and funding from NRC IRAP to support preclinical confirmation, manufacturing in Canada, and regulatory work for a lung-directed immunomodulator intended for prevention and treatment of respiratory viral infections.
Oral presentation of Phase 2 clinical trial data for a GI-targeted immunomodulator showing clinical, endoscopic, and histologic responses in patients with moderate-to-severe Crohn’s disease.
Regulatory clearance to proceed with a randomized placebo-controlled trial evaluating lung-directed immunomodulator in elderly participants to assess effects on innate immunity and respiratory infection outcomes.
Awarded grant funding by the Accelerating Clinical Trials (ACT) consortium to support a Phase 2 perioperative trial assessing reduction of postoperative immune suppression in late-stage colon cancer.
Three-year ARD grant to support preclinical and translational research to expand indications for organ-targeted immunomodulators.